Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)

We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Leo I., Karmali, Reem, Kaplan, Jason B., Popat, Rakesh, Burris, Howard A., Ferrari, Silvia, Madan, Sumit, Patel, Manish R., Gritti, Giuseppe, El-Sharkawi, Dima, Chau, F. Ian, Radford, John, de Oteyza, Jaime Pérez, Zinzani, Pier Luigi, Iyer, Swaminathan P., Townsend, William, Miao, Harry, Proscurshim, Igor, Wang, Shining, Katyayan, Shilpi, Yuan, Ying, Zhu, Jiaxi, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882996/
https://www.ncbi.nlm.nih.gov/pubmed/36702329
http://dx.doi.org/10.18632/oncotarget.28352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882996/
https://www.ncbi.nlm.nih.gov/pubmed/36702329
http://dx.doi.org/10.18632/oncotarget.28352

Ejemplares similares